Veracity Capital LLC Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Veracity Capital LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 134.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 2,523 shares of the biotechnology company’s stock after acquiring an additional 1,446 shares during the period. Veracity Capital LLC’s holdings in United Therapeutics were worth $890,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares during the period. 1832 Asset Management L.P. acquired a new stake in shares of United Therapeutics during the second quarter worth about $1,562,000. Evergreen Capital Management LLC purchased a new position in United Therapeutics in the second quarter valued at $375,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in shares of United Therapeutics by 52.7% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 8,565 shares of the biotechnology company’s stock valued at $2,728,000 after buying an additional 2,955 shares during the period. Finally, Toronto Dominion Bank grew its holdings in United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after acquiring an additional 37 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the transaction, the chief financial officer now directly owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,848 shares of company stock valued at $55,165,099 in the last 90 days. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Up 0.2 %

UTHR stock opened at $371.89 on Friday. The business’s 50-day simple moving average is $365.04 and its 200 day simple moving average is $355.24. The company has a market cap of $16.60 billion, a PE ratio of 16.33, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the firm posted $5.38 EPS. The business’s revenue was up 22.9% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on UTHR. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. HC Wainwright upped their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.